Drugging RAS: Know the enemy

Bjoern Papke, Channing J. Der

Research output: Contribution to journalReview article

  • 40 Citations

Abstract

The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.

LanguageEnglish (US)
Pages1158-1163
Number of pages6
JournalScience
Volume355
Issue number6330
DOIs
StatePublished - Mar 17 2017

Fingerprint

Neoplasms
Growth and Development
Oncogenes
Genes
Technology
Therapeutics
Research
Direction compound

ASJC Scopus subject areas

  • General

Cite this

Drugging RAS : Know the enemy. / Papke, Bjoern; Der, Channing J.

In: Science, Vol. 355, No. 6330, 17.03.2017, p. 1158-1163.

Research output: Contribution to journalReview article

Papke, Bjoern ; Der, Channing J. / Drugging RAS : Know the enemy. In: Science. 2017 ; Vol. 355, No. 6330. pp. 1158-1163.
@article{e511e6d6f0214eb9b570fa160d507cb0,
title = "Drugging RAS: Know the enemy",
abstract = "The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.",
author = "Bjoern Papke and Der, {Channing J.}",
year = "2017",
month = "3",
day = "17",
doi = "10.1126/science.aam7622",
language = "English (US)",
volume = "355",
pages = "1158--1163",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6330",

}

TY - JOUR

T1 - Drugging RAS

T2 - Science

AU - Papke, Bjoern

AU - Der, Channing J.

PY - 2017/3/17

Y1 - 2017/3/17

N2 - The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.

AB - The three RAS oncogenes make up the most frequently mutated gene family in human cancer. The well-validated role of mutationally activated RAS genes in driving cancer development and growth has stimulated comprehensive efforts to develop therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite more than three decades of research effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception that RAS may be undruggable. However, with a greater appreciation of the complexities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is experiencing renewed excitement that mutant RAS may finally be conquered. Here we summarize where these efforts stand.

UR - http://www.scopus.com/inward/record.url?scp=85015320989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015320989&partnerID=8YFLogxK

U2 - 10.1126/science.aam7622

DO - 10.1126/science.aam7622

M3 - Review article

VL - 355

SP - 1158

EP - 1163

JO - Science

JF - Science

SN - 0036-8075

IS - 6330

ER -